• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2001 Fiscal Year Final Research Report Summary

Prediction of anticancer effect of 1-p-D-arabinofuranosylcytostee by sensitive monitoring of its intracellular active metabolite in leukemic cells

Research Project

Project/Area Number 10670938
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionFukui Medical University

Principal Investigator

UEDA Takanori  Fukui Medical University Department of Medicine Professor, 医学部, 教授 (40160171)

Co-Investigator(Kenkyū-buntansha) YAMAUCHI Takahiro  Fukui Medical University University Hospital Assistant Professor, 医学部・附属病院, 助手 (90291377)
Project Period (FY) 1998 – 2001
Keywordsara-C / BHAC / acute leukemia / tailor- made therapy / ara-CTP / DNA incorporation / cellular TDM / in vitro pharmacokinetic
Research Abstract

1. Pharmacokinetic study of ara-CTP, an intracellular active metabolite of ara-C.
ara-CTP was measured in leukemic cells by the newly established sensitive method in 25 leukemic patients receiving ara-C or log-acting ara-C, BHAC at low or conventional doses. The ara-CTP concentrations differed by the administration methods, doses, and patients, and were not predicted from the plasma ara-C concentrations. As the maintenance of the plasma ara-C was important for the retention of ara-CTP in the cell, continuous infusion of ara-C and BHAC produced ara-CTP efficiently. In BHAC therapy, patients with complete remission achieved greater ara-CTP amounts than those without remission, suggesting that ara-CTP would 6e a crucial parameter for the therapeutic efficacy of BHAC. Myelosuppression was correlated to the plasma ara-C level, suggesting that normal hematopoietic stem cells have similar sensitivity to ara-C among individuals.
2. Detection of ara-C incorporated into DNA.
The detection method fo … More r ara-C incorporated into DNA was established. DNA was separated from acid insoluble fraction of leukemic cells after treatment with ara-C. The DNA was digested enzymatically to nucleosides that included ara-C. ara-C was isolated by high performance liquid chromatography, followed by liophilization. The recovery of each step was over 90 %. Radioimmunoassay will be applied to the isolated sample using anti-ara-C serum to confirm its ara-C concentration.
3. Cytotpxic effects evaluated by a new computer-controlled in vitro pharmacokinetic simulation system.
Cytotoxicity was compared between a pharmacokinetically simulated condition and a conventional culture system condition. The survival rates of the cell line K562 incubated with the simulated ara-C infusions for 2, 4, 8, and 16 h demonstrated that the cytotoxicity of ara-C was time-dependent. In contrast, under a conventional culture system, no time-dependent inhibition was observed. Similarly, the simulations of the infusion of daunorubicin for 0.5, 2, 4, and 8 h revealed that the cytotoxic effect of daunorubicin was concentration-dependent Less

  • Research Products

    (13 results)

All Other

All Publications (13 results)

  • [Publications] Takanori Ueda: "Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : The ALL90 study of the Japan Adult Leukemia Study Group"Int. J. Hematol.. 68. 279-289 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Shinji Kishi: "Evaluation of cell-killing effects of 1-β-D-Arabinofuranosyloytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system"Cancer Res.. 59. 2629-2637 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Haruyuki Takemura: "Simultaneous treatment with 1-β-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells"Cancer Res.. 61. 172-177 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Takahiro Yamauchi: "Monitoring of intracellular 1-β-D-arabinofuranosyloytosine 5'-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low-and conventional-doses"Jpn. J. Cancer Res.. 92. 546-553 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Takahiro Yamauchi: "Close correlation of 1-β-D-arabinofuranosylcytosinc 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N^4-behenoyl-1-β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia"Jpn. J. Cancer Res.. 92. 975-982 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Toshihiro Fukushima: "A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma : relationship with leukocytopenia and neutropenia"Int. J. Hematol.. 74. 297-302 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 上田孝典: "白血病とAra-C大量療法"大野竜三編、医薬ジャーナル社. 8 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Takaisi Ueda: "Resjiffise-oriented individualized induction therapy with six drags followed bv four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group."

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shinji Kishi: "Evaluationf of cell-killing effects of 1-β-D-Arabinofuranosylcytosine and daunorubicin bv a new computer-controlled in vitro pharmacokinetic simulation system."Cancer Res. 59. 2629-2637 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Haruvuki Takemura: "Simultaneous treatment with 1-β-D-arabinofuranosvlcvtosine and rfannnnihirin nuniras I cross-resistance to both drugs due to a combinationspecific mechanism in HL60 cells."Cancer Res.

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Takahiro Yamauchi: "Monitoring of intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low- and conventional- doses."Jpn. J. Cancer Res. 92. 546-553 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Takahiro Yamauchi: "Close correlation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N^4-behenoyl-1-β-Darabinofuranosylcytosine therapy for acute myelogenous leukemia."Jpn. J. Cancer Res. 92. 975-982 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Toshihiro Fukushima: "A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia."fInt. J. Hematol.

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2003-09-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi